RSS | Login | Register

Cefaclor Capsules

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare Cefaclor Capsules to:

Generic Name for Cefaclor Capsules

Cefaclor 250mg, 500mg; caps.

Legal Classification:

Pharmacological Class for Cefaclor Capsules

Cephalosporin.

Manufacturer of Cefaclor Capsules

Various generic manufacturers

Indications for Cefaclor Capsules

Susceptible infections including otitis media, lower respiratory or urinary tract, pharyngitis/tonsillitis, skin and skin structure.

Adult dose for Cefaclor Capsules

250–500mg every 8 hrs.

Children's dosing for Cefaclor Capsules

<1month: not recommended. ≥1month: 20mg/kg per day in 3 equally divided doses. Otitis media, more serious or less susceptible infections: 40mg/kg per day in 3 equally divided doses (may give in 2 divided doses for pharyngitis or otitis media); max 1g/day.

Also:

Cefaclor Extended-Release Tablets

Cefaclor Suspension

Warnings/Precautions for Cefaclor Capsules

Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefaclor Capsules

May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. CD: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.

Adverse Reactions for Cefaclor Capsules

Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.

How is Cefaclor Capsules supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.